90Y-Anditixafortide (90Y-Pentixather) is the therapeutic analogue of 68Ga-Pentixafor, to be used in metastasized patients showing tumors expressing CXCR4. 90Y-Anditixafortide was developed in parallel to 177Lu-Pentixather in priority in patients with multiple myeloma and eventually showed superiority.
Further studies have now been initiated (Phase II) with this drug.
Target/Mechanism: CXCR4
Carrier/Ligand: Pentixather
Radiation Type: beta electrons (β–)